A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

This study is testing whether combining two newer treatments — teclistamab (a bispecific antibody) and mezigdomide (an oral immune-modulating drug) — can help people with multiple myeloma that has come back or stopped responding to prior therapies. **You may be eligible if...** - You have been diagnosed with multiple myeloma that has relapsed or is no longer responding to treatment - You have received at least 2 prior lines of therapy, including a proteasome inhibitor, an IMiD, and an anti-CD38 antibody - Your myeloma is measurable in blood, urine, or on imaging - Your organ function is adequate for treatment **You may NOT be eligible if...** - You have received certain prior treatments that conflict with teclistamab or mezigdomide eligibility - You have active infections or serious organ problems - Your bone marrow function is too compromised to receive treatment safely Talk to your doctor to see if this trial is right for you.